# CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

> **NCT04704323** · PHASE1 · RECRUITING · sponsor: **Catapult Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Lymphocytic Leukemia, Chronic
- SLL

## Interventions

- **DRUG:** CAP-100

## Key facts

- **NCT ID:** NCT04704323
- **Lead sponsor:** Catapult Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704323, "CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04704323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*